The short answer
ApoB (apolipoprotein B) is a blood test that counts the particles able to carry cholesterol into your artery walls. LDL cholesterol tells you how much cholesterol those particles hold; ApoB tells you how many particles there are. When the two disagree, guidelines treat ApoB as the better guide to risk.
What ApoB is
Every LDL particle, and every other particle that can lodge in an artery wall, carries exactly one ApoB protein. So an ApoB result is a head count of those particles. Two people with the same LDL cholesterol can have very different particle counts, which is common with high triglycerides, diabetes or excess weight around the middle.
The test is a standard blood draw. It needs no fasting, and labs report it in mg/dL in the US and g/L in much of Europe (1 g/L = 100 mg/dL).
What the guidelines say
No guideline gives one ApoB number for everyone. They set goals by how high your overall cardiovascular risk already is. The US guideline also treats ApoB as a second check, used once LDL cholesterol goals are met.
| Source | ApoB level | What it means there |
|---|---|---|
| ESC/EAS 2019 | below 100 mg/dL | Secondary goal for people at moderate risk |
| ESC/EAS 2019 | below 80 mg/dL | Secondary goal for people at high risk |
| ESC/EAS 2019 | below 65 mg/dL | Secondary goal for people at very high risk |
| ACC/AHA 2026 | below 90 mg/dL | Goal for lower-risk adults |
| ACC/AHA 2026 | below 70 mg/dL | Goal for higher-risk adults |
| ACC/AHA 2026 | below 55 mg/dL | May be considered for people at very high risk |
| ACC/AHA 2026 | 120 mg/dL or above | A “risk-enhancing factor” that can tip a treatment decision |
Where longevity doctors go further
This is the marker where the gap is widest. Peter Attia, the physician behind Outlive, argues that guidelines wait too long and aim too high. His stated position is that about 60 mg/dL should be the ceiling for everyone, roughly the lowest 5% of the population, and that lowering should start by a person’s late 30s or early 40s rather than after risk has built up.
The reasoning is that artery damage depends on how many particles you carry and for how many years, so a number that is “fine for now” still adds up over decades. The guideline view is more cautious for a reason: getting most people to 60 means medication, and the trials that prove benefit were run in people at higher risk, not in healthy 40-year-olds. By the guideline tables I am under the goal for lower-risk people. By Attia’s ceiling I am 27 points over. Both statements are true, and that is the conversation I am having with my doctor.
Attia is not alone. Allan Sniderman, the McGill cardiologist whose research built much of the case for ApoB, calls the evidence overwhelming and wants it measured routinely alongside the standard panel. The National Lipid Association says that when ApoB and LDL cholesterol disagree, risk follows ApoB.
Bryan Johnson, the entrepreneur who publishes his own lab results, reportedly aims below 60, the same line as Attia.
What changes the reading
ApoB is fairly stable from day to day, which is part of its appeal. Over months it responds to the same things LDL cholesterol does: what you eat, body weight, thyroid function, and lipid-lowering medication. Genetics set much of the baseline, so two people with similar habits can sit far apart.
My numbers
I first tested ApoB in February 2026: 94 mg/dL. In October 2026 it was 87 mg/dL. I am getting closer to my own target of under 80 mg/dL.
What I’m doing about it
I care about this one. Managing it well could pay off for decades. This year I have kept a low-carb, Mediterranean-style diet and taken omega-3, and between February and October my ApoB fell from 94 to 87 mg/dL. That is a small but important improvement, and I can’t tell you which part did it.
In November 2026 I started two new things: a daily soluble-fibre supplement (psyllium) and more fatty fish. I plan to retest every six months, so the next result will show whether they move it further.
How it fits your biological age
ApoB is not one of the nine markers in the PhenoAge formula, so it does not move the calculator’s result. It answers a different question: PhenoAge summarises overall aging risk from routine bloodwork, while ApoB looks at one cause of heart disease directly. In the app I track both.
Questions
Is ApoB better than LDL cholesterol?
For most people the two agree. When they disagree, the ESC/EAS guidelines say ApoB is the more accurate measure of risk, especially with high triglycerides, diabetes or obesity.
Do I need to fast for an ApoB test?
No. ApoB barely changes after a meal.
My lab report has no ApoB. Why?
It is not part of the standard lipid panel in most countries. You usually have to ask for it by name.
See where you stand
The free calculator turns nine standard blood markers into a biological age in about a minute.
Sources
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–1295. https://pmc.ncbi.nlm.nih.gov/articles/PMC7369156/
- National Lipid Association. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus. https://www.lipid.org/nla/role-apolipoprotein-b-clinical-management-cardiovascular-risk-adults-expert-clinical-consensus